PT Esa Medika Mandiri Tbk (EMMI) has expressed strong optimism regarding the prospects of the medical device industry in Indonesia. The company, engaged in the trade of laboratory, pharmaceutical, and medical equipment, is preparing to conduct an initial public offering (IPO) as a strategic effort to strengthen operations and scale up domestic manufacturing production.
According to prospectus data, the medical technology market in Indonesia is predicted to experience rapid growth with a compound annual growth rate (CAGR) reaching 8.68% between 2025 and 2030, with an estimated market value of US$4.02 billion. This opportunity is considered wide open given that currently over 75% of national medical equipment needs still rely on imported products.
The Indonesian government, through its healthcare transformation policy, continues to encourage the use of domestic products by increasing the Domestic Component Level (TKDN). EMMI's position is further strengthened by a distribution network that reaches more than 200 healthcare institutions, particularly government hospitals, as well as manufacturing facilities located in Cikupa and Solo.
To bolster profitability, EMMI has begun venturing into the consumables segment, such as surgical suture production through strategic partnerships with global entities. This initiative is designed to generate more stable recurring revenue and reduce dependence on short-term projects.
In this corporate action, EMMI is issuing 522.85 million new shares at Rp470 per share, successfully raising fresh funds reaching Rp245.74 billion. The allocation of these funds will be used for debt repayment, working capital financing, and capital expenditure for building a new factory in Cikupa to strengthen future national medical production capacity.
